Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Multiple Myeloma 251Lymphoma 128Leukemia, Myeloid, Acute 103Lymphoma, Non-Hodgkin 98Precursor Cell Lymphoblastic Leukemia-Lymphoma 93Neoplasms, Plasma Cell 91Myelodysplastic Syndromes 91Leukemia 79Hodgkin Disease 78Lymphoma, Large B-Cell, Diffuse 66Leukemia, Lymphocytic, Chronic, B-Cell 65Lymphoma, Mantle-Cell 59Lymphoma, Follicular 57Neuroblastoma 44Burkitt Lymphoma 44Lymphoma, Large-Cell, Immunoblastic 40Lymphoma, B-Cell, Marginal Zone 37Recurrence 34Myeloproliferative Disorders 32Hematologic Neoplasms 32Leukemia, Myelogenous, Chronic, BCR-ABL Positive 30Immunoglobulin Light-chain Amyloidosis 29Leukemia, Myeloid, Accelerated Phase 25Leukemia, Myeloid, Chronic-Phase 24Congenital Abnormalities 24Leukemia, Myelomonocytic, Chronic 23Graft vs Host Disease 23Dendritic Cell Sarcoma, Interdigitating 21Waldenstrom Macroglobulinemia 20Melanoma 20

Interventions

Dexamethasone 4Electroencephalography 3XENP 1595 2Methods 2selinexor 1pomalidomide 1ixazomib 1fasudil 1birtamimab 1UE2343 1Transurethral Resection of Bladder 1Telemedicine 1Tablets 1Surgical Procedures, Operative 1Standard of Care 1Rosiglitazone 1Propofol 1Positron-Emission Tomography 1Neurofeedback 1Methotrexate 1Melphalan 1Mass Screening 1Magnetic Resonance Imaging 1Lysine Acetyltransferase 5 1Hypnosis 1Hormones 1Exercise 1Ethanol 1Drug Delivery Systems 1Donepezil 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Alzheimer Disease × Melphalan × Clear all
NCT01083316 2020-09-25

Bortezomib and Dexamethasone Followed by High-Dose Melphalan and Stem Cell Transplantation for Primary (AL) Amyloidosis

Boston Medical Center

Phase 2 Completed
35 enrolled 9 charts
Plasma cell

Immunoglobulin Light-chain Amyloidosis, Alzheimer Disease, Amyloidosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡